The FDA’s decision is a win for vaccine makers Pfizer, Moderna and Novavax, which have all been developing versions of their Covid shots to target XBB.1.5.
FDA recommends that updated Covid shots target omicron subvariant XBB.1.5 this fall
Posted in Uncategorized.